The Supreme Court of Ohio unanimously ruled that generic-drug maker Perrigo Sales Corp. correctly calculated its commercial activity tax from the money it actually received after distributor chargebacks, not from the higher list prices printed on invoices. The Sept. 22 decision affirmed the Ohio Board of Tax Appeals and rejected the state tax commissioner's attempt to collect additional tax for the 2016-through-2018 audit period, according to the court's case summary.
Perrigo sells prescription drugs through wholesalers but negotiates lower contract prices with retailers such as pharmacies. A wholesaler initially receives an invoice using the wholesale acquisition cost, then claims a chargeback reflecting the difference between that figure and the retailer's contract price. In about 97% of the transactions examined, Perrigo received only the net amount after that adjustment, the court found in its opinion.
What the justices decided
Ohio's commercial activity tax applies to taxable gross receipts for the privilege of doing business in the state. The current statute specifies that the levy falls on the person receiving those receipts and is not a transaction tax imposed directly on the buyer. The dispute centered on a related definition: what amount Perrigo had actually “realized” from its sales.
Justice R. Patrick DeWine, writing for the court, concluded that the list price was an accounting starting point rather than money Perrigo collected. The tax commissioner characterized chargebacks as business expenses that could not be deducted from gross receipts. The court rejected that framing because Perrigo never received the chargeback amount in the first place. It therefore held that the net payment from distributors was the taxable receipt.
The ruling leaves the Board of Tax Appeals' 2025 decision intact and gives other businesses a clearer test for pricing systems in which invoice amounts are routinely adjusted before payment. A tax analysis of the board's ruling noted that companies with comparable price reductions may need to review whether their Ohio filings already track only the amount ultimately received. The Supreme Court's decision now makes that interpretation binding for the Perrigo dispute.
Why the case matters
The result is significant beyond pharmaceuticals because Ohio's commercial activity tax is based on receipts rather than profit. Businesses may not subtract ordinary costs merely because those costs reduce their margin. But the court drew a different line where an invoiced figure was never collected and the parties understood that a contractual adjustment would establish the actual sale price.
That distinction does not automatically resolve every rebate, discount or chargeback arrangement. The opinion relied on the structure and evidence in Perrigo's transactions, including the rapid reconciliation of chargebacks and the parties' shared expectation that the wholesaler would remit the net amount. Companies considering changes to prior returns would still need to compare their own contracts and accounting records with the facts the court accepted.
For the Department of Taxation, the decision limits the use of nominal invoice prices when auditing similar transactions. For taxpayers, it confirms that Ohio's gross-receipts base begins with economic payment actually received, while leaving the broader prohibition against deducting ordinary business expenses in place.
